| Catalog No. |
Size |
Price |
Figures |
|---|
Z00367-10 ug
| 10 ug | $ 91.00 |
References:
- Dayer JM, et al. Adipose Tissue Has Anti-Inflammatory Properties: Focus on IL-1 Receptor Antagonist (IL-1Ra). Ann. N. Y. Acad. Sci. Jun 2006; 1069: 444-453.
- Bessler H, et al. Postoperative pain, morphine consumption, and genetic polymorphism of IL-1beta and IL-1 receptor antagonist. Neurosci. Lett. Aug 2006; 404(1-2): 154-158.
|
|---|
Z00367-50 ug
| 50 ug | $ 300.00 |
|---|
Z00367-1 mg
| 1 mg | $ 1600.00 |
|---|
| Full Name | | Interleukin (IL)-1 Receptor Antagonist, human |
|
| Abbreviated Name-1 | rHuIL-1ra |
|---|
| Abbreviated Name-2 | IL1 Receptor Antagonist; Interleukin-1 Receptor Antagonist; Interleukin1 Receptor Antagonist |
|---|
| Description | Interleukin-1 receptor antagonist (IL-1ra) is a member of the IL-1 family. Endogenous IL-1ra is produced in numerous animal disease models as well as in human autoimmune and chronic inflammatory diseases. It binds to IL-1 receptors in competition with IL-1, but does not elicit intracellular response from this binding. Its role in counteracting the proinflammatory effects of IL-1 is being studied by numerous research groups. IL-4 and IL-13 have been shown to amplify the stimulatory effect of IL1-beta on the production of soluble and intracellular forms of IL1-ra. The regulated expression of IL1ra in various cell types has been shown to be influenced by cytokines. In synovial fibroblasts the synthesis of IL-1ra is markedly enhanced by IL-1 , TNF-alpha , or PDGF. Recombinant Human IL-1RN produced in E. coli is a non-glycosylated, N-terminal methionyl form of the human naturally-occurring polypeptide chain containing 153 amino acids and having a molecular mass of 17,258 Da. |
|---|
| Source | E. coli |
|---|
| M.W. | 17,258 Da |
|---|
| Purity | Greater than 95.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel. |
|---|
| Endotoxin Level | Less than 0.1 ng/µg (IEU/µg) of IL-1 ra. |
|---|
| Specific Activity | The ED50 as determined by the dose-dependant inhibition of IL-1 stimulation of D10S cells was found to be 0.5 ng/ml, corresponding to a Specific Activity of 2.0×106 IU/mg. |
|---|
| Storage | Lyophilized rHuIL-1 ra although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution rHuIL-1ra should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid repeated freeze-thaw cycles. |
|---|
| Formulation | IL-1RN was lyophilized after extensive dialysis against PBS. |
|---|
| Reconstitution | It is recommended to reconstitute the lyophilized rHuIL-1ra in sterile 18 MΩ-cm H2O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions. |
|---|
| Quantitation |
|
|---|
| Sequence analysis | The sequence of the first five N-terminal amino acids was determined and was found to be Met-Arg-Pro-Ser-Gly. |
|---|
